Juan Li , Xiao-Song Hu , Fang-Fang Zhou Shuai Li You-Sheng Lin Wen-Qian Qi Cun-Fang Qi , Xiao Zhang
1 Experiment Technology Center of Preclinical Medicine of Chengdu Medical College, Chengdu, Sichuan Province, China
2 Department of Anatomy, Qinghai University, Xining, Qinghai Province, China
Abstract Integrity of the blood-brain barrier structure is essential for maintaining the internal environment of the brain. Development of cerebral infarction and brain edema is strongly associated with blood-brain barrier leakage. Therefore, studies have suggested that protecting the blood-brain barrier may be an effective method for treating acute stroke. To examine this possibility, stroke model rats were established by middle cerebral artery occlusion and reperfusion. Remote ischemic postconditioning was immediately induced by three cycles of 10-minute ischemia/10-minute reperfusion of bilateral hind limbs at the beginning of middle cerebral artery occlusion reperfusion. Neurological function of rat models was evaluated using Zea Longa’s method. Permeability of the blood-brain barrier was assessed by Evans blue leakage. Infarct volume and brain edema were evaluated using 2,3,5-triphenyltetrazolium chloride staining. Expression of matrix metalloproteinase-9 and claudin-5 mRNA was determined by real-time quantitative reverse transcription-polymerase chain reaction. Expression of matrix metalloproteinase-9 and claudin-5 protein was measured by western blot assay. The number of matrix metalloproteinase-9- and claudin-5-positive cells was analyzed using immunohistochemistry. Our results showed that remote ischemic postconditioning alleviated disruption of the blood-brain barrier, reduced infarct volume and edema, decreased expression of matrix metalloproteinase-9 mRNA and protein and the number of positive cells, increased expression of claudin-5 mRNA and protein and the number of positive cells, and remarkably improved neurological function. These findings confirm that by suppressing expression of matrix metalloproteinase-9 and claudin-5 induced by acute ischemia/reperfusion, remote ischemic postconditioning reduces blood-brain barrier injury, mitigates ischemic injury, and exerts protective effects on the brain.
Key Words: nerve regeneration; remote ischemic postconditioning; middle cerebral artery occlusion; cerebral ischemia/reperfusion; bloodbrain barrier; acute cerebral ischemia; stroke; matrix metalloproteinase-9; claudin-5; neural regeneration
In recent decades, stroke has become one of the leading causes of disability and death worldwide. Despite advances in understanding of the pathogenesis of cerebral ischemia, few therapeutic options are available for acute ischemic stroke(Donnan et al., 2008). Currently, tissue plasminogen activator administered intravenously within 3 hours of symptom onset is the only Food And Drug Administration-approved therapy for rescuing brain tissue and re-establishing blood flow after acute ischemic stroke (Tilley et al., 1997). Nevertheless, mainly because of the extremely short therapeutic time window,only a small percentage of patients qualify for this treatment(Montano et al., 2013). Therefore, the current lack of clinical treatments for acute brain ischemia requires investigation of novel approaches that may eventually lead to feasible clinical application.
Recently, numerous investigators have confirmed that ischemic postconditioning (IPc) can alleviate cerebral ischemic injury in transient or permanent middle cerebral artery occlusion(MCAO) models (Zhao et al., 2006; Xing et al., 2008; Chen et al., 2016). As a new approach to induce ischemic tolerance,remote IPc (RIPc) is an endogenous protective approach, in which implementation of several brief cycles of non-infarct ischemia and reperfusion to an organ or tissue renders remote organs or tissues resistant to severe and sustained ischemia/reperfusion injury (Li et al., 2006; Lim and Hausenloy, 2012;Drunalini Perera et al., 2014). However, the underlying protective mechanisms are not well known.
Accumulating evidence demonstrates that breakdown of the blood-brain barrier (BBB) is a leading factor in many brain diseases, including ischemic stroke (Lee et al., 2013; Panahpour et al., 2014). Recently, many studies have shown that as an important member of matrix metalloproteinases (MMPs)(Chaturvedi and Kaczmarek, 2014), MMP-9 plays a dominant role in BBB disruption by further hydrolyzing tight junctions and the extracellular matrix, thereby leading to BBB breakage,brain edema, inflammatory cell exudation, and intracranial hemorrhage (Lakhan et al., 2013; Li et al., 2013; Yang et al.,2013; Jickling et al., 2014; Lv et al., 2016). As one substrate of MMP-9, claudin-5 is now widely accepted as a fundamental component of paracellular permeability and a key contributor to tight junction formation and BBB integrity (Liao et al., 2016;Lv et al., 2016).
To date, there has been little research on the effect of RIPc on structural and functional changes of the BBB induced by cerebral ischemia injury, although possible protective mechanisms of RIPc against brain injury after ischemic stroke have been described (Ren et al., 2009; Chen et al., 2014). Here, we examined the effect of RIPc on BBB disruption after ischemic stroke. Further, we also clarified whether RIPc alleviates BBB leakage by regulating critical molecules such as MMP-9 and claudin-5 in adult rats after acute ischemia reperfusion injury.
Animal use protocols were approved by the Institutional Animal Care and Use Committee at Chengdu Medical College of China (Approval No. 201401120411). The experimental procedure followed the United States National Institutes of Health Guide for the Care and Use of Laboratory Animal (NIH Publication No. 85-23, revised 1985).
A total of 81 adult female specific-pathogen-free Sprague-Dawley rats aged 15–16 weeks and weighing 250–280 g were provided by the Dashuo of Laboratory Animal Co.,Ltd., Chengdu, China (License No. SYXK (Chuan) 2014-189). Rats were housed on a 12-hour dark-light cycle in specific-pathogen-free facilities at the Animal Center of Chengdu Medical College of China.
All rats were randomly assigned into three groups (n = 27 per group): sham group (sham operation), MCAO group, and RIPc group (MCAO with RIPc).
All animals were allowed free access to water and food, but were fasted for 12 hours before surgery. Rats were intraperitoneally anesthetized with chloral hydrate (350 mg/kg). The transient focal MCAO model was established as previously described (Xiong et al., 2003), but with minor modifications.Briefly, the right common carotid artery, external carotid artery,and internal carotid artery were exposed in turn. A 5 cm 4-0 monofilament nylon suture with a blunt tip was inserted into the common carotid artery to block the initial segment of the MCA.The filament was softly advanced 18–20 mm along the internal carotid artery from the branch point of the carotid artery, until there was mild resistance. Sixty minutes after MCAO, reperfusion was initiated by gentle withdrawal of the monofilament. In the sham group, all surgical procedures were performed, but with no occlusion. Deep body temperature was monitored using a rectal probe and maintained at 36.2–37.2° C using light and a heating pad throughout the experiment. The skin was closed and the rat returned to its cage.
Limb RIPc was induced immediately by three cycles of 10-minute ischemia/10-minute reperfusion of bilateral hind limbs at the beginning of MCAO reperfusion, as described in previous methods (Ren et al., 2011; Cheng et al., 2014) but with slight modifications. Bilateral proximal hind limbs of each rat were encircled with rubber bands and pulse sensors placed on bilateral dorsalis pedis artery areas. Reversible ischemia of bilateral hind limbs was produced by tying the rubber bands as tight as possible until blood flow in the limbs was blocked. Blood flow of bilateral hind limbs was completely prevented as confirmed by hypothermia and cyanosis in the hind limbs and disappearance of a pulse. Limb ischemia was maintained for 10 minutes,and then reperfusion achieved by relaxing the rubber band for 10 minutes.
Ten minutes before being sacrificed (24 hours after reperfusion),rats were neurologically evaluated by three observers blinded to the animal groups. According to Zea Longa’s method (Longa et al., 1989), only rats scoring 1–2 were used for the following experimental procedure. Standard assessment was as follows: 0 point, neurological symptoms not obvious; 1 point, left forelimb cannot stretch completely; 2 points, rat rotates to the left;3 points, rat falls to the left side; and 4 points, no spontaneous walking with a depressed level of consciousness. Final neurobehavioral scoring was performed according to a previous study(Garcia et al., 1995), with average scores finally obtained. Criteria included the following six tests: (1) spontaneous activity(0–3 points); (2) movement symmetry (0–3 points); (3) forepaw outstretching (0–3 points); (4) climbing (1–3 points); (5)body proprioception (1–3 points); and (6) vibrissae touching response (1–3 points). Minimum score was 3 and maximum score was 18.
Deep anaesthesia was achieved, and then transcardial perfusion was performed for all rats at 24 hours after reperfusion.According to the requirements of different experimental techniques, rats were also randomly divided into groups for:2,3,5-triphenyltetrazolium chloride (TTC) staining (n = 8 per group), real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (n = 5 per group), Evans blue detection (n = 5 per group), western blot assay (n = 5 per group),and histological investigation (n = 4 per group). Ischemic rats were excluded from the study if evidence of a subarachnoid hemorrhage was found during brain tissue sampling.
Figure 1 Effect of RIPc on neurological function, cerebral infarction, cerebral edema, and blood-brain barrier integrity in stroke rats.
For morphological staining, rats were first quickly cleaned with 0.9% NaCl at 4°C, and then slowly pre-fixed with 4%paraformaldehyde (pH 7.3) at 4°C. After rapid removal of the brains, coronal brain slices were obtained from bregma −2 to 2 mm, and post-fixed in 4% paraformaldehyde for 24 hours,then embedded in paraffin and cut into 5-µm-thick coronal sections.
To evaluate BBB permeability, Evans blue leakage into brain tissue was detected after intravenous injection. Briefly, 2%Evans blue (4 mL/kg) (Sigma–Aldrich, Steinheim, Germany)diluted in 0.9% NaCl was injected into the tail vein at 1 hour before the animal was sacrificed. Rats were transcardially perfused with normal saline to wash away remaining dye in the blood vessels. Next, each brain was rapidly removed, dissected,weighed, and ischemic hemispheres cut into fine particles and then immersed in methanamide (1 mL/100 mg) for 24 hours at 60° C. Following centrifugation at 12,000 × g for 20 minutes,absorption of supernatant was detected at 630 nm with an ultraviolet spectrophotometer (Bio-Rad, Hercules, CA, USA). Evans blue content was quantified as micrograms of Evans blue per gram of ischemic hemisphere using a standardized curve, with methanamide as negative control.
Brains were immediately collected and dissected into 2 mm coronal slices. Six continuous sections were immersed in TTC solution (0.5% TTC in PBS) at 37°C for 30 minutes, and then fixed in 4% paraformaldehyde buffer. Infarcted brain tissue retained its pale color, whereas living tissue was stained red.Sections were imaged using a digital camera (Olympus, Tokyo,Japan). The infarction zone was measured and analyzed by Image software (IPP, version 6.0, Media Cybernetics, Inc., Rockville, MD, USA). Using an indirect method (Lin et al., 1993), a corrected ratio of infarction to normal volume was calculated as follows: percentage of corrected infarct volume = contralateral hemisphere area−(ipsilateral hemisphere − infarction area measured)/contralateral hemisphere area × 100%. Cerebral edema was assessed in sections stained by TTC according to the formula: ipsilateral volume − contralateral volume/contralateral volume × 100%.
Brain tissue for each group was rapidly obtained from the right hemispheric MCA territory. Total RNA was isolated using Trizol reagent (Invitrogen, Waltham, MA, USA) according to the manufacturer’s protocol, and then reverse transcribed to generate cDNA with the Revert Aid TM First Strand cDNA Synthesis kit (TaKaRa Biotechnology, Dalian, China). cDNA was used as template in real-time PCR to analyze expression levels of target genes. The primer sequences used were: MMP-9,forward: 5′-TCC TAC TCT GCC TGC ACC A-3′; reverse: 5′-CAG TTA CAG TGA CGT CGG CT-3′; claudin-5, forward: 5′-CTG CCC ATG TGG CAG GTG A-3′; reverse: 5′-TGC ATG TGC CCG GTG CTC T-3′; and β-actin forward: 5′-GAA GAT CAA GAT CAT TGC TCC T-3′; reverse: 5′-TAC TCC TGC TTG CTG ATC CA-3′. Reverse transcription reactions were amplified using a Bio-Rad CFX96 Detection System (Bio-Rad)with the Plexor™One-Step qRT-PCR System (Promega, Madison, WI, USA). The PCR conditions were: pre-denaturation at 95° C for 5 minutes, denaturation at 95° C for 30 seconds,annealing at 51° C for 30 seconds, and extension at 72° C for 1 minute. All operations were performed for 45 cycles. Relative expression quantities were calculated by normalization to β-actin values using the 2-ΔΔCtmethod.
Brain meninges was carefully removed and ischemic brain tissue homogenized on ice in a lysis buffer containing 0.05 M Tris-HCl, 0.5 M ethylenediamine tetraacetic acid, 30% Triton-X-100, NaCl, 10% sodium dodecyl sulphate, and 1 mM phenylmethyl sulfonylfluoride. Homogenates were centrifuged at 12,000 r/min for 5 minutes at 4°C. The supernatant was collected and stored at −80 ° C for further use. Next, 20 µL samples were loaded onto each lane and electrophoresed on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis for 2.5 hours at a constant voltage of 120 V. Proteins were transferred onto polyvinylidene difluoride membranes after electrophoresis. Membranes were blocked in 5% low fat milk in Tris-buffered saline-Tween-20, incubated at 37°C for 60 minutes with antibodies. Membranes were analyzed using Enhanced Chemiluminescence (Bio-Rad Laboratories, Philadelphia, PA, USA). The following primary antibodies were used:rabbit anti-MMP-9 (poly-antibody, 1:2000; Abcam, Cambridge, UK) and rabbit anti-claudin-5 (poly-antibody,1:1000;Abcam). The secondary antibody was goat anti-rabbit IgG(1:400; Proteintech Group, Wuhan, Hebei Province, China).Expression of target proteins was determined using β-actin protein (rabbit anti-β-actin poly-antibody, 1:8000; Abcam)as a loading control. The optical density intensity of each band was measured using BIO-RAD ChemiDoc XRS and Quantity One software (Bio-Rad). The optical density value in the sham group was used as the baseline reference value, with the ratio of each group to the sham group representing change.
Sections were dried, dewaxed, hydrated, and underwent high-pressure antigen retrieval. After immersion in 0.3% H2O2at 37°C for 10 minutes, all sections were then blocked with 5% normal goat serum at 37°C for 20 minutes. Next, sections were incubated with primary anti-MMP-9 polyclonal antibody (rabbit, 1:100; Abcam) or anti-claudin-5 polyclonal antibody (rabbit, 1:200; Abcam) at 4°C overnight. After washing in PBS, sections were incubated with Polink-1 HRP DAB Detection System (goat anti-rabbit; Zhongshan, Beijing,China) at 37 ° C for 1 hour, visualized using 3,3′-diaminobenzidine, and counterstained with hematoxylin. Control sections were incubated in PBS instead of primary antibody. For each section, total number of positive cells in ischemic brain was counted in five different fields around the infarct area in a blinded manner using an Olympus BX-53 microscope (Olympus) at 400× magnification. Data from four rats in each group were averaged.
After standard histological procedures, sections were treated by high pressure antigen retrieval for 2 minutes and blocked with 5% goat serum at 37°C for 20 minutes. Afterwards,sections were incubated overnight at 4°C in mixtures of anti-MMP-9 antibody (rabbit, polyclonal, 1:50; Abcam)/anti-glial fibrillary acidic protein (GFAP) (mouse, monoclonal, 1:200; Proteintech), anti-claudin-5 antibody (rabbit,polyclonal, 1:100; Abcam)/anti-GFAP (mouse, monoclonal,1:200; Proteintech), anti-MMP-9 antibody (rabbit, polyclonal,1:50; Abcam)/anti-NeuN (mouse, monoclonal, 1:200; Abcam),anti-claudin-5 antibody (rabbit, polyclonal, 1:100; Abcam)/anti-NeuN (mouse, monoclonal, 1:200; Abcam), or anti-claudin-5 antibody (rabbit, polyclonal, 1:100; Abcam)/anti-MMP-9(mouse, monoclonal, 1:50; Abcam). After washing in PBS, sections were incubated with fluorescence secondary antibody IgG(monoclonal, anti-mouse Alexa Fluor488-conjugated, green,1:100; Proteintech)/IgG (polyclonal, anti-rabbit Alexa Fluor 594-conjugated, red, 1:100; Proteintech) for 2 hours at 37°C.After DAPI mounting, sections were imaged using a fluorescence microscope (Olympus).
All data were analyzed by an investigator blinded to treatments,and presented as mean ± SEM. Differences in quantitative data were evaluated by one-way analysis of variance followed by Student’s t-test. A value of P < 0.05 was considered statistically significant. Statistical analysis was performed with SPSS 17.0 software (SPSS, Chicago, IL, USA).
Using the 18-point scale of Garcia et al., (1995), rats in the sham group showed nearly no neurological deficits. Neurological deficit scores in the MCAO group and RIPc group were also recorded. Scores were higher in the RIPc group than the MCAO group. These results demonstrate that neurological outcome is markedly improved after RIPc treatment (Figure 1A).
The protective effect of RIPc on cerebral infarction was assessed by calculating cerebral infarct volume with TTC staining.The results show that no ischemic damage was detected in the sham group. Compared with the MCAO group, infarct volume (Figure 1B, C) and edema (Figure 1D) were significantly reduced in the RIPc group (41.9 ± 6.4% and 27.6 ± 3.1%reduction, respectively) (P < 0.05). To estimate the influence of RIPc on BBB integrity after acute cerebral ischemic stroke,Evans blue leakage was detected. As expected, Evans blue content was very low in the sham group. Compared with the sham group, Evans blue transudation in the MCAO and RIPc groups markedly increased, and was mainly distributed in the ipsilateral striatum and cortex. Furthermore, compared with the MCAO group, Evans blue leakage was significantly diminished in the RIPc group (P < 0.05; Figure 1E). These results show that RIPc markedly attenuates damage of the BBB caused by transient focal cerebral ischemia.
We used qRT-PCR to detect expression of MMP-9 mRNA in the different groups. Expression of MMP-9 mRNA was very low in the sham group, but increased visibly in the MCAO and RIPc groups. Compared with the MCAO group, expression of MMP-9 mRNA was significantly decreased in the RIPc group(P < 0.05; Figure 2A).
Further, levels of MMP-9 protein were examined by western blot assay. Our results show very low levels of MMP-9 protein in the sham group (Figure 2B). While after cerebral ischemia/reperfusion, levels of MMP-9 protein were significantly increased in both the RIPc and MCAO groups compared with the sham group (P < 0.01; Figure 2C). Overexpression of MMP-9 induced by stroke was markedly inhibited by RIPc treatment.
In the cortical ischemic penumbra, immunohistochemistry showed that MMP-9 was mainly expressed in the cytoplasm of neurons (MMP-9 and GFAP double-positive cells) (Figure 2E),with expression in only a few astrocytes (MMP-9 and NeuN double-positive cells) (Figure 2D). In the sham group, almost no MMP-9 labeled cells were apparent in the brain. However, MMP-9 immunostaining was significantly enhanced in the MCAO and RIPc groups (P < 0.01; Figure 2F, G). Furthermore, MMP-9-positive cell number was less in the RIPc group compared with the MCAO group (P < 0.05; Figure 2G).
Expression of the gene for claudin-5 (Cldn5) was reduced in both the MCAO group and RIPc group compared with the sham group (P < 0.05; Figure 3A). While expression of claudin-5 mRNA after ischemia/reperfusion was lower in the MCAO group than RIPc group (P > 0.05). Levels of claudin-5 protein were examined by western blot assay (Figure 3B). The results showed that claudin-5 protein levels were significantly decreased in both the MCAO and RIPc groups compared with the sham group (P < 0.01). Moreover, compared with the RIPc group, reduction of claudin-5 was significant in the MCAO group (P < 0.05; Figure 3C).
Immunohistochemistry showed that claudin-5 immunoreactivity was detected on endothelial cells of brain microvessels(claudin-5 and GFAP double-positive cells) (Figure 3D) and individual neurons (claudin-5 and NeuN double-positive cells)(Figure 3E). Indeed, there was more positive staining than the sham group (P < 0.01; Figure 3F, G). Number of claudin-5 immunopositive cells was greater in the RIPc group than the MCAO group (P < 0.05; Figure 3G).
Many studies have confirmed that IPc is a powerful protective strategy against brain injury after stroke in rats (Du et al., 2014;Gulati and Singh, 2014; Wang et al., 2014; Zhao et al., 2014).Moreover, extensive research into the protective mechanisms underlying IPc has been performed, with multiple factors found to be involved including suppression of oxidative stress, activation of signaling pathways, decrease of apoptosis, and inhibition of endoplasmic stress (Pignataro et al., 2008; Yuan et al., 2011).Considering the potential limitations of the clinical application of IPc, it soon became evident that the concept could also be used for distant organs. As a distant organ, the limb was chosen and RIPc performed before the onset of myocardial reperfusion.This proved effective and feasible for protecting the myocardium from ischemia reperfusion (Li et al., 2006). Subsequently,Ren et al., (2009) found that RIPc remarkably decreased infarct volume following permanent focal cerebral ischemia. Given the current potential clinical role and simple operational procedure,limb RIPc has attracted widespread interest, and is generally considered a creative and promising approach for protecting important organs or tissue from injury factors of severe acute ischemia (Li et al., 2006; Lim and Hausenloy, 2012).
In most studies, RIPc was performed promptly at the start of reperfusion, and indeed a relatively narrow time window for a protective effect has been noted (Anrather and Hallenbeck,2013). Furthermore, Xu et al., (2014) suggested that rapid RIPc can exert its maximum protective effect if the accumulative time of limb occlusion/reperfusion lasted from 40 to 60 minutes. In this study, we chose a procedure of 10-minute ischemia and 10-minute reperfusion for three cycles (therefore an overall accumulation of 60 minutes), and consistently confirmed that this dramatically reduced infarct size. Although identifying the molecular mechanisms underlying RIPc is only just beginning, to date a growing body of evidence has indicated that RIPc might share common triggers, mediators,effectors, and mechanistic signaling pathways with classical intra-organ ischemic preconditioning/postconditioning and inter-organ remote limb preconditioning (Pan et al., 2016).After repeated brief sub-irreversible injurious ischemia/reperfusion in a distant organ (limb) or tissue, lactate/pyruvate ratio due to anaerobic glycolysis accumulates within minutes, ultimately leading to acidosis (Kauffman and Albuquerque, 1970).Subsequently, a drop in tissue pH can activate sensitive sensory neurons, resulting in marked activation of afferent neural pathways (Kauffman and Albuquerque, 1970). Meanwhile, activation of endothelium, blood cells, and platelets (Strecker et al.,2005; Doeuvre et al., 2009) leads to release of protective neural,humoral, or cellular transmitters from remote organs (Anrather and Hallenbeck, 2013), reaching the target organ (brain)through neural pathways and/or blood circulation, which may activate prosurvival pathways (phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K]/Akt and extracellular signal–regulated kinase [ERK]) or suppress proinflammatory pathways(P38/ mitogen-activated protein kinase [MAPK] and toll-like receptors [TLRs]), thereby leading to remote ischemic tolerance (Noshita et al., 2002; Valen, 2009; Rohailla et al., 2014).
Figure 2 Effect of limb RIPc on transcription and expression of MMP-9 in ischemic brain.
Anatomical structure of the BBB includes the cerebral microvascular endothelium, which together with astrocytes, pericytes,neurons, and the extracellular matrix, comprises a “neurovascular unit” that is indispensable for homeostasis and function of the central nervous system (del Zoppo, 2009; Dong et al.,2009). Since increased BBB permeability is often associated with brain edema and swelling (Wang and Shuaib, 2007; Lee et al., 2013), BBB leakage may result in central nervous system dysfunction, and even endanger patient life. Recent studies with IPc have shown that some drugs or early exercise can attenuate cerebral ischemia injury by improving BBB structure and function (Zhang et al., 2013; Liu et al., 2014b). Nevertheless, little is known about whether non-invasive RIPc can protect the brain from ischemic damage through the same mechanism. Here, we detected structural integrity of the BBB by Evans blue extravasation in a MCAO reperfusion rat model with RIPc intervention.As expected, our results show that local ischemia for 60 minutes results in marked BBB damage and cerebral edema. Further,at the early stage of ischemic stroke, infarct volume or cerebral edema enlarged correspondingly while Evans blue transudation increased, which was suppressed by RIPc treatment. This finding is consistent with previous studies (Cheng et al., 2014; Liu et al., 2014a). Therefore, we have confirmed that RIPc can exert protective effects on cerebral ischemia injury by stabilizing BBB structure and function.
Figure 3 Effect of limb RIPc on transcription and expression of claudin-5 in the cortex.
Numerous animal studies and clinical data have shown that MMP-9 protein levels are visibly up-regulated in serum and brain tissue during acute ischemic stroke, which correlates with cerebral infarct volume and disease severity (Lee et al.,2009; Demir et al., 2012). Here, we show that transcription and expression of MMP-9 are up-regulated after reperfusion, and obviously inhibited by RIPc treatment. These results are consistent with previous studies (Guo et al., 2008; Liu et al., 2012).Growing evidence shows that proinflammatory pathways and downstream transcription factors (e.g., nuclear factor [NF]-κB and activator protein 1 [AP]-1) can enhance MMP-9 promoter activity and activate MMP-9 gene transcription (Yang et al., 2015). Furthermore, the MMP-9 gene promoter comprises a highly conserved motif that matches a NF-κB p65 binding component, while suppression of NF-κB inhibits MMP-9 up-regulation in ischemic brain (Cheng et al., 2006). Overall,we deduced that RIPc might inhibit ischemia-triggered MMP-9 over-regulation by suppressing activation of the NF-κB gene and corresponding pathways. It is currently accepted that increased MMP-9 is strongly associated with BBB disruption via extracellular matrix breakdown, whereas BBB damage can be attenuated by both reducing MMP-9 and deleting the MMP-9 gene (Guo et al., 2008; Liu et al., 2012; Yang et al.,2015).
It is well-known that tight junctions are continuous specialized membrane strands located at the most apical region between cerebral endothelial cells, and comprise a close complex of various proteins including transmembrane and cytoplasmic proteins. (Horstmann et al., 2003; Lv et al., 2016). As a predominant component of the BBB, claudin-5 regulates paracellular permeability of the BBB through the actin cytoskeleton via interaction with TJ proteins, including occludin, junctional adhesion molecule-1, claudin-1, zonula occludens (ZO) proteins, and caveolin-1 (CAV-1). Decreased expression of claudin-5 can open the BBB, leading to brain edema and neuronal cell death (Yang et al., 2007). Since claudin-5 is a component of the BBB that maintains stability, claudin-5 transcription and expression were detected in this study to determine whether brain protection of RIPc treatment is involved in alteration of claudin-5, at least partially. Our results indicate that RIPc visibly inhibits the decrease in claudin-5 protein. Wolburg et al.,(2009) found that astrocytic end feet help regulate cerebral microvessel blood flow, which is dedicated to both maintenance and creation of the BBB microenvironment. In the present study, a few claudin-5-positive cells were co-located in astrocytes, especially around microvessels. Thus, our results indicate that structural stability of the BBB relies on subtle molecular regulation of astrocytes. However, contrary to our expectation,reduced Cldn5 transcription was not significantly suppressed by RIPc treatment. Indeed, we believe transcription of Cldn5 is earlier than subsequent protein expression.
In summary, RIPc can improve neurological function, reduce cerebral infarct volume and edema, and alleviate BBB leakage,ultimately leading to cerebral ischemia tolerance. The underlying neuroprotective mechanism induced by RIPc may involve decreased overexpression of MMP-9 and suppressed degradation of claudin-5 after transient focal ischemic stroke. Finally,our study has shortcomings. For improved and more impartial evaluation of the role of RIPc, we should further observe ultrastructural damage to the BBB after acute cerebral ischemia, and perform reperfusion for a longer time.
Author contributions: CFQ, XZ, XSH and JL conceived and designed the study. XSH, JL, SL, YSL and WQQ performed the experiments. CFQ obtained the funding. XSH and JL wrote the paper. XSH, JL, CFQ and XZ reviewed and edited the manuscript. All authors read and approved the final version of the manuscript.
Conflicts of interest: We declare that we have no conflict of interest.
Financial support: This study was supported by the National Natural Science Foundation of China, No. 30960107; the Natural Science Foundation of the Education Department of Sichuan Province of China, No. 14ZA0223. The funders had no role in study conception and design, literature retrieval, experimental studies, data acquisition and analysis, statistical analysis, paper writing and decision to submit the paper for publication.
Institutional review board statement: The study protocol was approved by the Institutional Animal Care and Use Committee at Chengdu Medical College of China (approval No. 201401120411). The experimental procedure followed the United States National Institutes of Health Guide for the Care and Use of Laboratory Animal (NIH Publication No. 85-23, revised 1985).
Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.
Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.
Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.
Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Open peer reviewer: Nahid Aboutaleb, Iran University of Medical Sciences, Iran.
Additional file: Open peer review report 1.